⌘K

16:05:00·120d

PRReleasevia Quantisnow

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

ByQuantisnow·Wall Street's wire, on your screen.

MGRX· Mangoceuticals Inc.

Health Care

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study | Quantisnow